companiesCompany
Deciphera Pharmaceuticals (Ono)
Kinase-switch-control company behind ripretinib for GIST and vimseltinib for tenosynovial giant cell tumour; bought by Ono Pharmaceutical in 2024.
Ripretinib (Qinlock, 2020; INVICTUS, INTRIGUE, INSIGHT) and vimseltinib (Romvimza, approved 14 February 2025; MOTION). Acquired by Ono for ~$2.4B (2024).
ApprovedSmall-molecule kinase inhibitor (KIT/PDGFRA switch-control)
Ripretinib · Qinlock
A fourth-line GIST drug that locks KIT in an off state regardless of which resistance mutation the tumour has acquired.
ApprovedSmall-molecule kinase inhibitor (CSF1R)
Vimseltinib · Romvimza
Vimseltinib is a pill approved in February 2025 for tenosynovial giant cell tumour, a benign but destructive joint tumour, offering an alternative to repeated surgery.